The short answer
Reported effects span gastrointestinal lesion and fistula models, tendon and ligament repair, vascular effects and more. Nearly all are rat models from one research group. Clinical development occurred as PL-14736 for inflammatory bowel disease, and a Phase 2 is recruiting.
Key facts
- Gastrointestinal
- Lesion and fistula models
- Musculoskeletal
- Tendon, ligament, muscle
- Vascular
- Angiogenesis, blood vessel effects
- Clinical
- PL-14736 for IBD; Phase 2 recruiting
- Dominant model
- Rat
- Receptor
- None identified
Sorted by how well established
Best supported: the gastrointestinal work, which is the oldest thread, the closest to the compound's proposed origin, and the one that reached clinical development as PL-14736. Then the musculoskeletal work, with two studies in the Journal of Orthopaedic Research and a human trial now testing it. Then the vascular findings, which may underlie the others. Least supported: the broader claims that follow from breadth rather than from any specific study.
The gastrointestinal thread
Lesion models and fistula healing recur throughout, and Sikirić and colleagues reported on fistula healing in Current Pharmaceutical Design in 2020. This is the thread that made it to human trials for inflammatory bowel disease, reported in Inflammopharmacology in 2006, which makes it the most developed line of evidence the compound has.
Research material referenced
BPC-157 5mg, third-party HPLC tested
The musculoskeletal thread
Krivic 2006 on Achilles detachment and Cerovecki 2010 on ligament healing, both in the Journal of Orthopaedic Research. This is the thread the current Phase 2 trial tests, in acute hamstring muscle strain, meaning a preclinical line is about to meet a randomised placebo-controlled human endpoint.
What is absent
A molecular target. Substantial independent replication outside the Zagreb group. And any reported clinical result: the Phase 1 record has not been updated and the Phase 2 has not completed. None of these absences refutes the preclinical findings; together they mark the boundary of what can be said.
How it compares within this library
BPC-157 has the most clinical development of any compound in these categories, and one of the weaker mechanistic pictures. DSIP has neither. GHK-Cu has better-defined chemistry and no clinical programme. TB-500 has a clearer molecular function and no trials. That combination of real clinical progress on an unmapped mechanism is unusual.
Frequently asked questions
What is BPC-157 best supported for?
The gastrointestinal work, which is the oldest thread and the one that reached clinical development as PL-14736 for inflammatory bowel disease.
Is there a clinical result?
No. The Phase 1 record has not been updated and the Phase 2 trial has not completed; primary completion is due February 2027.
How does it compare to the other compounds here?
It has the most clinical development and one of the weakest mechanistic pictures, which is an unusual combination.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al., Fistulas Healing: BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., BPC 157 in trials for IBD. Inflammopharmacology 2006 (PMID 17186181)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 Side Effects and the Absence of Human DataNo controlled human safety study exists. What the rodent literature reports, the theoretical concern that follows from its own mechanism, and what nobody knows.
- What BPC-157 Is Claimed to Do, and in Which SpeciesTendon, ligament, gut and vascular findings - almost entirely in rats. What has been demonstrated, in which species, and why no human timeline exists.
- Is BPC-157 Legal?Not a controlled substance, and not a licensed medicine either. What that gap means, plus the FDA compounding decision and its prohibited status in sport.
- Why BPC-157 and TB-500 Are Called the Wolverine StackAn informal name for combining two repair-studied peptides, after the comic character who heals fast. What the name promises and what the literature supports.
- Is Oral BPC-157 Absorbed? What the Rat Data ShowsUnlike most peptides, BPC-157 was given orally in the original rodent work and still produced effects. What that does and does not establish for a capsule.